BCRX - BioCryst Pharmaceuticals, Inc.
| Previous close | 4.86 |
| Open | 4.89 |
| Bid | 4.92 x 700 |
| Ask | 4.93 x 700 |
| Day's range | 4.83 - 5.01 |
| 52-week range | 3.95 - 7.39 |
| Volume | 196,773 |
| Avg. volume | 1,010,508 |
| Market cap | 485.142M |
| Beta | 1.74 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings date | 2 May 2018 - 7 May 2018 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.83 |
- Business Wire•15 days ago
BioCryst Pharmaceuticals and Idera Pharmaceuticals Reschedule Meetings to Vote on Proposed Merger
BioCryst Pharmaceuticals, Inc. and Idera Pharmaceuticals, Inc. today jointly announced that they have each rescheduled their respective Special Meetings of Stockholders to vote on the proposed merger of BioCryst and Idera to July 10, 2018 at 10:00 AM ET.
- Business Wire•23 days ago
BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals
BioCryst Pharmaceuticals, Inc. today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the pending merger of BioCryst and Idera.
- Associated Press•2 months ago
BioCryst reports 4Q loss
The Durham, North Carolina-based company said it had a loss of 20 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- Zacks•2 months ago
Options Traders Expect Huge Moves in BioCryst (BCRX) Stock
Investors in BioCryst (BCRX) need to pay close attention to the stock based on moves in the options market lately.
- Zacks•3 months ago
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
- Zacks•3 months ago
BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
- Motley Fool•3 months ago
BioCryst Pharmaceuticals' and Idera Pharmaceuticals' Merger Announcement Gets No Love
Is this a merger out of weakness and necessity? Wall Street might think so.
- Motley Fool•4 months ago
Here's Why BioCryst Pharmaceuticals Gained as Much as 15.7% Today
An analyst upgraded the stock to start off the new year.
- Associated Press•6 months ago
BioCryst reports 3Q loss
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
